2024年欧洲肿瘤内科学会亚洲年会（ESMO ASIA 2024）将于当地时间12月6日~8日在新加坡召开，旨在展示和讨论亚洲地区肿瘤学领域的最新临床科研进展，进一步推动学术交流和共同进步。近日ESMO ASIA官网已公布相关研究题目，本期肿瘤资讯特别整理泌尿生殖系统肿瘤领域在优选口头报告专场（Proffered Paper session）和迷你口头报告专场（Mini Oral session）中的摘要标题，以飨读者。
优选口头报告专场
摘要号：268O
Title：Determinants of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor therapy response in renal cell carcinoma
标题：肾细胞癌中新辅助免疫检查点抑制剂联合酪氨酸激酶抑制剂疗效的决定因素
讲者：Liangyou Gu（北京，中国）
摘要号：269O
Title：Enfortumab Vedotin Plus Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Pan-Asian Subgroup Analysis From EV-302/KEYNOTE-A39
标题：Enfortumab Vedotin联合帕博利珠单抗（EV+P）与化疗（Chemo）治疗既往未治疗的局部晚期或转移性尿路上皮癌（la/mUC）：EV-302/KEYNOTE-A39泛亚亚组分析
讲者：Eiji Kikuchi（日本）
摘要号：270O
Title：Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone in Asian patients with previously untreated unresectable or metastatic urothelial carcinoma (u/mUC) from CheckMate 901
标题：CheckMate 901中纳武利尤单抗（NIVO）联合吉西他滨-顺铂（GC）与单独使用GC 在未经治疗的不可切除或转移性尿路上皮癌（u/mUC）亚洲患者中的效果对比
讲者：Yoshihiko Tomita（日本）
摘要号：271O
Title：Interim analysis (IA) of SPADE: a prospective, real-world study of avelumab first-line maintenance (1LM) treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Asia-Pacific (APAC) region
标题：SPADE中期分析（IA）：一项针对亚太地区（APAC）局部晚期或转移性尿路上皮癌（la/mUC）患者（pts）进行阿维鲁单抗一线维持（1LM）治疗的前瞻性、真实世界研究
讲者：Jungmin Jo（韩国）
摘要号：LBA2
Title：Belzutifan Versus Everolimus for Previously Treated Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up of the East Asian Subgroup of the Randomized Phase 3 LITESPARK-005 Trial
标题：Belzutifan与依维莫司在既往经治疗的晚期透明细胞肾细胞癌（ccRCC）中的疗效对比：随机3期LITESPARK-005试验东亚亚组的最新随访结果
讲者：Jae-Lyun Lee（韩国）
迷你口头报告专场
摘要号：272MO
Title：PUNCH01: Interim results from a phase II study of intra‑arterial chemotherapy（IAC）combined with Tislelizumab and Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC)
标题：PUNCH01：动脉化疗（IAC）联合替雷利珠单抗和卡介苗（BCG）治疗高危非肌层浸润性膀胱癌（HR NMIBC）的II期临床试验中期结果
讲者：Zongren Wang（广州，中国）
摘要号：273MO
Title：DURANCE: A phase Ib/II study to assess the safety and activity of Durvalumab (MEDI4736) in combination with S-488210/S-488211 Vaccine in Non-muscle invasive bladder Cancer
标题：DURANCE：一项旨在评估度伐利尤单抗（MEDI4736）与S-488210/S-488211疫苗联合治疗非肌层浸润性膀胱癌的安全性和活性的Ib/II期研究
讲者：Gianmarco Leone（英国）
摘要号：274MO
Title：Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A single-arm, multicentre clinical trial
标题：呋喹替尼联合斯鲁利单抗作为晚期非透明细胞肾细胞癌（nccRCC）一线治疗的疗效和安全性：一项单臂、多中心临床试验
讲者：黄吉炜（上海，中国）
摘要号：275MO
Title：Neoadjuvant Sacituzumab Govitecan, followed by radical cystectomy, for Patients With Muscle-Invasive Bladder Cancer (MIBC): Updated Interim Results of SURE-01 trial
标题：新辅助戈沙妥珠单抗治疗后进行根治性膀胱切除术用于治疗肌层浸润性膀胱癌（MIBC）患者：SURE-01试验的最新中期结果
讲者：Brigida A. Maiorano（意大利）
摘要号：276MO
Title：Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: a retrospective cohort study
标题：台湾局部晚期或转移性尿路上皮癌（la/mUC）患者（pts）的流行病学、治疗（tx）模式和临床结果：一项回顾性队列研究
讲者：Li-Nien Chien（中国台湾）
摘要号：336MO
Title：A Phase II Single-Arm, Open-Label Trial of Pamiparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with Deleterious Germline or Somatic BRCA1/2 Alterations or Homologous Recombination Deficiency (HRD): Interim Analysis of Efficacy
标题：帕米帕利治疗具有有害生殖细胞系或体细胞BRCA1/2变异或同源重组缺陷（HRD）的转移性去势抵抗性前列腺癌（mCRPC）患者的II期单臂开放标签试验：疗效中期分析
讲者：Diwei Zhao（广州，中国）
摘要号：337MO
Title：Efficacy and safety of rezvilutamide (Rez) plus androgen-deprivation therapy (ADT) in patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) aged ≤64, 65–74, and ≥75 years: post-hoc analysis of randomized phase 3 CHART trial
标题：瑞维鲁胺（Rez）联合雄激素剥夺疗法（ADT）对年龄≤64岁、65–74岁和≥75岁高容量、转移性、激素敏感性前列腺癌（mHSPC）患者的疗效和安全性：随机化3期CHART 试验的事后分析
讲者：叶定伟（上海，中国）
摘要号：338MO
Title：Efficacy and safety of Tislelizumab (T) combined with Gemcitabine and Cisplatin (GC) for patients with localized muscle-invasive bladder cancer (MIBC) after radical local surgery: a prospective, phase II study
标题：替雷利珠单抗（T）联合吉西他滨和顺铂（GC）治疗局部肌层浸润性膀胱癌（MIBC）患者根治性局部手术后的疗效和安全性：一项前瞻性II期研究
讲者：Ming Cao（上海，中国）
如有遗漏或错误，欢迎广大读者提醒及指正。
排版编辑：肿瘤资讯-丹忱
苏公网安备32059002004080号
